PDCD1 and neoplasm: The combination of PDCD1 (PD‐1) and CD274 (PD‐L1) can disrupt the immune environment, culminating in immune evasion by tumour cells, and these molecules can be targeted for therapeutic intervention using immune checkpoint inhibitors.32, 33